A nomogram for predicting major gastrointestinal bleeding in patients treated with rivaroxaban

References

• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2020;41(4):543–603.
   PubMed Web of Science ®Google Scholar
• Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s choice–European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9–82.
   PubMed Web of Science ®Google Scholar
• Chong DT, Andreotti F, Verhamme P, et al. Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian Pacific society of cardiology on strategies for thrombotic and bleeding risk management. European Cardiology. 2021;16:e23.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients. JAHA. 2017;6(2):e004517.
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152(5):1014–1022.e1.
   PubMed Web of Science ®Google Scholar
• Ingason AB, Hreinsson JP, Ágústsson AS, et al. Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study. Ann Intern Med. 2021;174(11):1493–1502.
   PubMed Web of Science ®Google Scholar
• Gu ZC, Wei AH, Zhang C, et al. Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(4):792–799.e61.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258–3264.
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol. 2011;58(4):395–401.
   PubMed Web of Science ®Google Scholar
• Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry. Thromb Haemost. 2008;100(1):26–31.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302–2311.
   PubMed Web of Science ®Google Scholar
• Shimomura A, Nagata N, Shimbo T, et al. New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: a cohort study. J Gastroenterol Hepatol. 2018;33(1):164–171.
   PubMed Web of Science ®Google Scholar
• Mori N, Sotomi Y, Hirata A, et al. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian data from the DIRECT registry). Am J Cardiol. 2019;124(7):1044–1048.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Desai J, Kolb JM, Weitz JI, et al. Gastrointestinal bleeding with the new oral anticoagulants–defining the issues and the management strategies. Thromb Haemost. 2013;110(2):205–212.
   PubMed Web of Science ®Google Scholar
• Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of national association of hospital cardiologists (ANMCO) and the Italian association of hospital gastroenterologists and endoscopists (AIGO). Eur J Intern Med. 2021;85:1–13.
   PubMed Web of Science ®Google Scholar
• Radaelli F, Fuccio L, Paggi S, et al. What gastroenterologists should know about direct oral anticoagulants. Dig Liver Dis. 2020;52(10):1115–1125.
   PubMedGoogle Scholar
• Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104(7):1633–1641.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, Caterina D, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. European Heart Journal. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Acosta RD, Abraham NS, Chandrasekhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3–16.
   PubMed Web of Science ®Google Scholar
• Cuschieri JR, Drawz P, Falck-Ytter Y, et al. Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. J Dig Dis. 2014;15(4):195–201.
   PubMed Web of Science ®Google Scholar
• de Groot NL, Hagenaars MP, Smeets HM, et al. Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts. J Gastroenterol. 2014;49(2):245–253.
   PubMed Web of Science ®Google Scholar
• Lv MN, Zheng XC, Zhang HQ, et al. Comparison of clinical performance of four gastrointestinal bleeding risk scores in Chinese patients with atrial fibrillation receiving oral anticoagulants. J Thromb Thrombolysis. 2021;51(1):136–142.
   PubMed Web of Science ®Google Scholar
• Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333(7571):726.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England J Med. 2001;345:494–502.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108(5):876–886.
   PubMed Web of Science ®Google Scholar
• Al-Hussainy N, Kragholm KH, Lundbye-Christensen S, et al. Safety and efficacy of direct oral anticoagulants in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study. European Heart J Qual Care Clin Outcomes. 2022;8(8):840–851.
   PubMed Web of Science ®Google Scholar
• Tomizawa M, Shinozaki F, Hasegawa R, et al. Reduced hemoglobin and increased C-reactive protein are associated with upper gastrointestinal bleeding. World J Gastroenterol. 2014;20(5):1311–1317.
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. Jama. 2018;320(21):2221–2230.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Eikelboom JW, Bosch J, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019;157(2):403–412.e5.
   PubMed Web of Science ®Google Scholar
• Lee SR, Kwon S, Choi EK, et al. Proton pump inhibitor co-therapy in patients with atrial fibrillation treated with oral anticoagulants and a prior history of upper gastrointestinal tract bleeding. Cardiovasc Drugs Ther. 2022;36(4):679–689.
   PubMed Web of Science ®Google Scholar
• Dong Y, He S, Li X, et al. Prevention of non-vitamin K oral anticoagulants-related gastrointestinal bleeding with acid suppressants: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2022;28:10760296211064897.
   Web of Science ®Google Scholar
• Kurlander JE, Rubenstein JH, Richardson CR, et al. Physicians’ perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey. Am J Gastroenterol. 2020;115(5):689–696.
   PubMed Web of Science ®Google Scholar
• Lanas A. Proton pump inhibitor (PPI) co-therapy and gastrointestinal bleeding with antithrombotic drugs: a step forward but not enough. Eur J Intern Med. 2021;85:23–24.
   PubMed Web of Science ®Google Scholar